Seven bullish things for MNTA that could occur at any time: • FDA approval of generic Copaxone. • Ruling from District Court on Copaxone Markman hearing. • A positive development in MNTA’s patent-infringement lawsuit against Teva. • A partnership deal for an FoB program. • A partnership deal for M402 (or, less likely, for M118). • Monetization of MNTA’s Lovenox income stream. • A buyout offer at a large premium.